Evaluation and validation of diagnostic tests for guiding therapeutic decisions;Évaluation et validation des tests diagnostiques dans le cadre du ciblage thérapeutique

Therapie

Volumn 64, Issue 3, 2009, Pages 195-201

  Landais, Paul ^a   Méresse, Valérie ^b   Ghislain, Jean Claude ^c   Arnaud, Olivier ^d   Bibeau, Frédéric ^e   Cellier, Dominic ^f   D'Enfert, Jérôme ^g   Eberlé, Frédéric ^h   Goestchel, Agnès ⁱ   Grognet, Jean Marc ^j   Janus, Catherine ^k   Kassaï Koupaï, Behrouz ^l   Laurent Puig, Pierre ^m   Maisonneuve, Pascale ^c   Nowak, Frédérique ^h   Paintaud, Gilles ⁿ   Robba, Laurence ^o  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c AFSSAPS   (France)

^d INSERM   (France)

^e CENTRE VAL D AURELLE   (France)

^f Merck Santé

^g Laboratoire Roche   (France)

^h Roche Diagnostics Meylan ^*  (Spain)

ⁱ GLAXOSMITHKLINE   (United Kingdom)

^j des Finances et de l'Emploi

^k Sanofi Aventis

^l EPICIM   (France)

^m HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁿ UNIVERSITY HOSPITAL OF TOURS   (France)

^o CNAMTS Direction du Service Médical   (France)

more..

Author keywords

Development; Diagnostic test; Drug; Recommendations; Theranostics

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMATINIB; IRINOTECAN; LAPATINIB; OXALIPLATIN; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; TRASTUZUMAB;

ANALYTIC METHOD; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DIAGNOSTIC TEST; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; DRUG MONITORING; EVALUATION; HUMAN; MEDICAL DECISION MAKING; MEDICINE; METASTASIS; MUTATION; NONHODGKIN LYMPHOMA; ONCOGENE K RAS; PREDICTION; PRIORITY JOURNAL; QUALITY CONTROL; REIMBURSEMENT; REVIEW; VALIDATION STUDY;

EID: 69049085074     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie/2009027     Document Type: Article

References (18)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69(3): 89-95
2. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20(3): 719-726 (Pubitemid 34111379)
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344 (11): 783-792 (Pubitemid 32222155)
4. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23 (19): 4265-4274 (Pubitemid 46207001)
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353 (16): 1659-1672 (Pubitemid 41464705)
6. Penault-Llorca F, Balaton A, Sabourin JC, et al. Immunochemistry evaluation of HER2 status in infiltration breast cancer: technical protocol and interpretation guidelines. Ann Pathol 2002; 22 (2): 150-157 (Pubitemid 34453863)
7. Phillips AK, Van Bebber S, Isssa AM. Diagnostics and biomarker development: priming the pipeline. Nature Reviews Drug Disccovery 2006; 5: 463-469 (Pubitemid 44136958)
8. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66 (8): 3992-3995
9. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26 (10): 1626-1634
10. Van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 26, No 15S (May 20 Supplement), 2008: 2
11. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359 (17): 1757-1766
12. Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008; 9 (10): 962-972
13. Picard S, Titier K, Etienne G, et al. Through imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007; 109 (8): 3496-3499 (Pubitemid 46572540)
14. Tuma RS. Disease progression in some cancers may be due to low blood levels of targeted therapies. J Natl Cancer Inst 2008; 100 (13): 912-913
15. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90 (6): 2188-2195 (Pubitemid 27392702)
16. Igarashi T, Kobayashi Y, Ogura M, et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol 2002; 13 (6): 928-943 (Pubitemid 34752689)
17. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008; 358 (11): 1109-1117
18. Vray M, Girault D, Hoog-Labouret N, et al. Méthodologie des essais cliniques de petits effectifs. Therapie 2004; 59 (3): 273-279